Randomisation and masking
DISEASE, REMISSION
RITAZAREM was an open-label, unblinded study. Patients who achieved disease remission by month 4 were randomised into the maintenance phase using a web-based system in a 1:1 ratio, to receive rituximab or azathioprine. They were stratified at randomisation according to:ANCA type: PR3-ANCA or MPO-ANCA.

